Results 221 to 230 of about 122,680 (303)
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes in youth with axial juvenile spondyloarthritis (axJSpA) initiating TNF inhibitor (TNFi).
Timothy G. Brandon +8 more
wiley +1 more source
Effects of open-label placebos and self-monitoring in skin-picking disorder: a randomized crossover trial. [PDF]
Schienle A, Wabnegger A, Tanzmeister S.
europepmc +1 more source
Placebos in medicine: medical paradoxes need disentangling [PDF]
Di Blasi, Zelda, Reilly, David
core +1 more source
Feasibility Study of a Novel App‐Based Anxiety Intervention for Autistic People
ABSTRACT At least 50% of autistic people experience clinically relevant anxiety symptoms. However, reasons for elevated rates of anxiety in autism remain poorly understood and there is a high unmet need for novel and adapted therapies for anxiety that are accessible to autistic people.
Bethany Oakley +18 more
wiley +1 more source
Open-Label-Placebos can reduce pain, but not indigestion during gluten challenge in chronic pain patients. [PDF]
Paschke-Dahl L, Klinger R.
europepmc +1 more source
Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani +4 more
wiley +1 more source
Lu Xuns Erzählung 'Yao' oder die Wirksamkeit eines Placebos [PDF]
Kubin, Wolfgang, Monschein, Ylva
core +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source

